The estimated Net Worth of Daniel Vitt is at least $3.07 Milion dollars as of 26 February 2024. Daniel Vitt owns over 14,000 units of Immunic stock worth over $594,133 and over the last 5 years he sold IMUX stock worth over $92,484. In addition, he makes $2,383,930 as President, Chief Executive Officer a Director at Immunic.
Daniel has made over 5 trades of the Immunic stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 14,000 units of IMUX stock worth $18,340 on 26 February 2024.
The largest trade he's ever made was buying 14,000 units of Immunic stock on 26 February 2024 worth over $18,340. On average, Daniel trades about 2,638 units every 101 days since 2019. As of 26 February 2024 he still owns at least 390,877 units of Immunic stock.
You can see the complete history of Daniel Vitt stock trades at the bottom of the page.
Dr. Daniel Vitt Ph.D. serves as President, Chief Executive Officer, Director of the Company. He is also managing director of Immunic Research GmbH in Halle (Saale). He joined Immunic in January 2017 from 4SC AG, a publicly listed stock company based in Martinsried, Germany, which he co-founded in 1997. At 4SC, he served as Chief Scientific Officer (CSO) and Chief Development Officer (CDO). As a member of the executive board, he was responsible for all research and development activities at 4SC group including four clinical stage products. Dr. Vitt studied chemistry in Siegen and Würzburg, Germany from 1989—1994 and graduated from the University of Würzburg. During his doctoral studies, he focused on the molecular design of small molecule therapeutics. In 1998, he received his Ph.D. from the Institute of Organic Chemistry at the University of Würzburg. Vitt’s extensive senior management experience in the life sciences industry, including as the Company’s Chief Executive Officer, qualify him to serve as a member of our board.
As the President, Chief Executive Officer a Director of Immunic, the total compensation of Daniel Vitt at Immunic is $2,383,930. There are no executives at Immunic getting paid more.
Daniel Vitt is 52, he's been the President, Chief Executive Officer a Director of Immunic since 2019. There are 7 older and 6 younger executives at Immunic. The oldest executive at Immunic, Inc. is Tamar Howson, 72, who is the Independent Director.
Daniel's mailing address filed with the SEC is 1200 AVENUE OF THE AMERICAS, SUITE 200, , NEW YORK, NY, 10036.
Over the last 5 years, insiders at Immunic have traded over $174,861 worth of Immunic stock and bought 176,506 units worth $558,583 . The most active insiders traders include Barclay A Phillips, Joerg Neermann a Duane Nash. On average, Immunic executives and independent directors trade stock every 74 days with the average trade being worth of $15,244. The most recent stock trade was executed by Daniel Vitt on 26 February 2024, trading 14,000 units of IMUX stock currently worth $18,340.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Immunic executives and other stock owners filed with the SEC include: